Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

被引：21

作者：

Santoni, Matteo ^{[1
]}

Massari, Francesco ^{[2
]}

Myint, Zin W. ^{[3
]}

Iacovelli, Roberto ^{[4
]}

Pichler, Martin ^{[5
]}

Basso, Umberto ^{[6
]}

Kopecky, Jindrich ^{[7
]}

Kucharz, Jakub ^{[8
]}

Buti, Sebastiano ^{[9
]}

Rizzo, Mimma ^{[10
]}

Galli, Luca ^{[11
]}

Buettner, Thomas ^{[12
]}

De Giorgi, Ugo ^{[13
]}

Kanesvaran, Ravindran ^{[14
]}

Fiala, Ondrej ^{[15
]}

Grande, Enrique ^{[16
]}

Zucali, Paolo Andrea ^{[17
,18
]}

Fornarini, Giuseppe ^{[19
]}

Bourlon, Maria T. ^{[20
]}

Scagliarini, Sarah ^{[21
]}

Molina-Cerrillo, Javier ^{[22
]}

Aurilio, Gaetano ^{[23
]}

Matrana, Marc R. ^{[24
]}

Pichler, Renate ^{[25
]}

Cattrini, Carlo ^{[26
]}

Buechler, Tomas ^{[27
]}

Seront, Emmanuel ^{[28
]}

Calabro, Fabio ^{[29
]}

Pinto, Alvaro ^{[30
]}

Berardi, Rossana ^{[31
]}

Zgura, Anca ^{[32
]}

Mammone, Giulia ^{[33
]}

Ansari, Jawaher ^{[34
]}

Atzori, Francesco ^{[35
]}

Chiari, Rita ^{[36
]}

Bamias, Aristotelis ^{[37
]}

Caffo, Orazio ^{[38
]}

Procopio, Giuseppe ^{[39
,40
]}

Bassanelli, Maria ^{[41
]}

Merler, Sara ^{[42
]}

Messina, Carlo ^{[43
]}

Kueronya, Zsofia ^{[44
]}

Mosca, Alessandra ^{[45
]}

Bhuva, Dipen ^{[46
]}

Vau, Nuno ^{[47
]}

Incorvaia, Lorena ^{[48
]}

Rebuzzi, Sara Elena ^{[49
,50
]}

Roviello, Giandomenico ^{[51
]}

Zabalza, Ignacio Ortego ^{[16
]}

Rizzo, Alessandro ^{[52
]}

机构：

[1] Macerata Hosp, Oncol Unit, Via Santa Lucia 2, I-62100 Macerata, Italy

[2] IRCCS Azienda Osped Univ Bologna, Med Oncol, Via Albertoni 15, Bologna, Italy

[3] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA

[4] Fdn Policlin Univ Agostino Gemelli IRCCS, Oncol Med, Rome, Italy

[5] Med Univ Graz, Dept Internal Med, Div Oncol, Augenbruggerplatz 15, A-8010 Graz, Austria

[6] Ist Oncol Veneto IOV IRCCS, Dept Oncol, Oncol Unit 3, Padua, Italy

[7] Univ Hosp Hradec Kralove, Dept Clin Oncol & Radiotherapy, Hradec Kralove, Czech Republic

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Uro Oncol, Warsaw, Poland

[9] Univ Parma, Univ Hosp Parma, Dept Med & Surg, Med Oncol Unit, Parma, Italy

[10] AOU Consorziale Policlin Bari, Div Med Oncol, Piazza G Cesare 11, I-70124 Bari, Italy

[11] Univ Hosp Pisa, Oncol Unit 2, I-56126 Pisa, Italy

[12] Univ Hosp Bonn UKB, Dept Urol, D-53127 Bonn, Germany

[13] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Dept Med Oncol, Meldola, Italy

[14] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[15] Charles Univ Prague, Univ Hosp Pilsen, Fac Med, Dept Oncol & Radiotherapeut, Plzen, Czech Republic

[16] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain

[17] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Milan, Italy

[18] IRCCS Humanitas Res Hosp, Dept Oncol, Milan, Italy

[19] IRCCS Osped Policlin San Martino, Genoa, Italy

[20] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Hematol & Oncol Dept, Mexico City, Mexico

[21] Azienda Osped Rilievo Nazl Cardarelli Napoli, UOC Oncol, Naples, Italy

[22] Hosp Ramon & Cajal, Dept Med Oncol, Madrid, Spain

[23] European Inst Oncol IRCCS, Med Oncol Div Urogenital & Head & Neck Tumours, IEO, Milan, Italy

[24] Ochsner Med Ctr, Dept Internal Med, Hematol Oncol, New Orleans, LA USA

[25] Med Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria

[26] Maggiore Car Univ Hosp, Dept Med Oncol, I-28100 Novara, Italy

[27] Charles Univ Prague, Thomayer Univ Hosp, Fac Med 1, Dept Oncol, Prague 14059, Czech Republic

[28] Ctr Hospitalier Jolimont, Dept Med Oncol, Haine St Paul, Haine Saint Paul, Belgium

[29] San Camillo Forlanini Hosp, Dept Oncol, Rome, Italy

[30] La Paz Univ Hosp, Med Oncol Dept, Madrid, Spain

[31] Univ Politecn Marche, Dept Med Oncol, AOU Ospedali Riuniti Marche, Ancona, Italy

[32] Carol Davila Univ Med & Pharm, Prof Dr Alexandru Trestioreanu Inst Oncol, Dept Oncol Radiotherapy, Bucharest, Romania

[33] Sapienza Univ Rome, Dept Radiol Oncol & Anatomo Pathol Sci, Viale Regina Elena 324, I-00185 Rome, Italy

[34] Tawam Hosp, Med Oncol, Al Ain, U Arab Emirates

[35] Azienda Osped Univ Cagliari, Unita Oncol Med, Cagliari, Italy

[36] Azienda Osped Ospedali Riuniti Marche Nord, UOC Oncol, Tuscany, Italy

[37] Natl & Kapodistrian Univ Athens, ATTIKON Univ Hosp, Sch Med, Propaedeut Dept Internal Med 2, Athens, Greece

[38] Santa Chiara Hosp, Med Oncol Unit, Trento, Italy

[39] Fdn IRCCS Ist Nazl Tumori, Dipartimento Oncol Med, Milan, Italy

[40] Osped Maggiore Cremona, Oncol Med, Cremona, Italy

[41] IRCCS Regina Elena Natl Canc Inst, Med Oncol 1, Rome, Italy

[42] Univ Verona, Verona Univ Hosp Trust, Dept Med, Sect Oncol,Sch Med, Verona, Italy

[43] ARNAS Civ, Oncol Unit, Palermo, Italy

[44] Natl Inst Oncol, Dept Genitourinary Med Oncol & Clin Pharmacol, Budapest, Hungary

[45] IRCCS FPO, Candiolo Canc Inst, Oncol, I-10060 Turin, Italy

[46] Army Hosp Res & Referral, Dept Med Oncol, New Delhi, India

[47] Champalimaud Clin Ctr, Urol Oncol, P-1400038 Lisbon, Portugal

[48] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy

[49] Osped San Paolo, Med Oncol, I-17100 Savona, Italy

[50] Univ Genoa, Dept Internal Med & Med Specialties DiMI, Genoa, Italy

来源：

TARGETED ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

CYTOREDUCTIVE NEPHRECTOMY; SUNITINIB; CANCER;

D O I：

10.1007/s11523-023-00978-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundImmuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC).ObjectiveThe ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients.Patients and MethodsPatients aged & GE; 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB).ResultsA total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p = 0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p < 0.001).ConclusionsOur study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations.

引用

页码：559 / 570

页数：12

共 50 条

[41] Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
Kikuta, Masato
Naito, Sei
Osawa, Takahiro
Numakura, Kazuyuki
Narisawa, Takafumi
Takai, Yuki
Yagi, Mayu
Sekine, Yuya
Tokairin, Ojiro
Shinohara, Nobuo
Habuchi, Tomonori
Tsuchiya, Norihiko
BMC CANCER, 2025, 25 (01)
[42] Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan
Harada, Ken-ichi
Sato, Ryo
Bando, Yukari
Sano, Asuka
Matsushita, Yuto
Tamura, Keita
Terakawa, Tomoaki
Furukawa, Junya
Fujimoto, Naohiro
Fujisawa, Masato
Miyake, Hideaki
INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 772 - 777
[43] Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia
Crumbaker, Megan
Guminski, Alexander
Gurney, Howard
Sabanathan, Dhanusha
Wong, Shirley
Pavlakis, Nick
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (02) : E45 - E49
[44] Real-world treatment trends for patients with advanced prostate cancer and renal cell carcinoma and their cost-a survey in Japan
Osawa, Takahiro
Sasaki, Keita
Machida, Ryunosuke
Matsumoto, Takashi
Matsui, Yoshiyuki
Kitamura, Hiroshi
Nishiyama, Hiroyuki
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (10) : 1062 - 1070
[45] Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
Santoni, Matteo
Aurilio, Gaetano
Massari, Francesco
Grande, Enrique
Matrana, Marc R.
Rizzo, Mimma
De Giorgi, Ugo
Incorvaia, Lorena
Martignetti, Angelo
Molina-Cerrillo, Javier
Zabalza, Ignacio Ortego
Mollica, Veronica
Rizzo, Alessandro
Battelli, Nicola
Porta, Camillo
CLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 285 - 295
[46] Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers
Verhaart, Saskia Lisa
Abu-Ghanem, Yasmin
Mulder, Sasja F.
Oosting, Sjoukje
Van Der Veldt, Astrid
Osanto, Susanne
Aarts, Maureen J. B.
Houtsma, Danny
Peters, Frank P. J.
Groenewegen, Gerard
Van Herpen, Carla M. L.
Pronk, Loes M.
Tascilar, Metin
Hamberg, Paul
Los, Maartje
Vreugdenhil, Gerard
Polee, Marco
Ten Tije, Albert J.
Haanen, John B. A. G.
Bex, Axel
van den Eertwegh, Alfonsus J.
CLINICAL GENITOURINARY CANCER, 2021, 19 (03) : 274.e1 - 274.e16
[47] Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma
Maruzzo, Marco
Basso, Umberto
Diminutto, Alberto
Roma, Anna
Zustovich, Fable
Brunello, Antonella
Fiduccia, Pasquale
Banzato, Alberto
Zattoni, Filiberto
Zagonel, Vittorina
FUTURE ONCOLOGY, 2016, 12 (07) : 909 - 919
[48] Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population
Millan, Braden
Breau, Rodney H.
Mallick, Ranjeeta
Wood, Lori
Rendon, Ricardo
Finelli, Antonio
So, Alan I.
Lavallee, Luke T.
Pouliot, Frederic
Bhindi, Bimal
Heng, Daniel
Drachenberg, Darrel
Tanguay, Simon
Dean, Lucas
Basappa, Naveen S.
Lattouf, Jean-Baptiste
Bjarnason, George
Lalani, Aly-Khan
Kapoor, Anil
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (07) : 328.e15 - 328.e23
[49] Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry
Strauss, Arne
Schmid, Marianne
Rink, Michael
Moran, Michael
Bernhardt, Stephan
Hubbe, Marcus
Bergmann, Lothar
Schlack, Katrin
Boegemann, Martin
FUTURE ONCOLOGY, 2021, 17 (18) : 2325 - 2338
[50] Real-world comparison of the efficacy of first-line therapies and the influence of risk factors in advanced renal cell carcinoma
Haack, Maximilian
Neuberger, Stephanie
Boerner, Jan Hendrik
Ziewers, Stefanie
Duwe, Gregor
Dotzauer, Robert
Haferkamp, Axel
Mager, Rene
DISCOVER ONCOLOGY, 2025, 16 (01)

← 1 2 3 4 5 →